A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie ...

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration by finding that drug manufacturers must obtain pre-approval from HRSA before implementing ...

There are several ways the 340B program negatively impacts employers, according to Gremminger. One is that when a drug is filled through the 340B channel instead of through the employers’ PBM ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the ...